Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus hypofractionated radiotherapy for refractory advanced breast cancer
ChiCTR2500098204Phase 2Not yet recruiting
- Sponsor
- Liuzhou People's Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in breast cancer and triple-negative breast cancer (TNBC), sponsored by Liuzhou People's Hospital. Primary endpoint: Objective response rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500098204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098204.